drugset
drugset / Trial / NCT03267732

A Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)

NCT03267732 ↗

Phase 1 Completed 24 enrolled Eli Lilly and Company ARMO BioSciences · collab
RandomizedParallel-groupOpen-labelBasic science

Summary

To evaluate the pharmacokinetics of single and multiple doses of pegilodecakin in healthy participants.

Timeline

Start
2017-09-05
Primary completion
2017-10-17
Completion
2017-10-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Pegilodecakin Protein / enzyme biologic 5 ug/kg Subcutaneous
Subject Pegilodecakin Protein / enzyme biologic 10 ug/kg Subcutaneous

Indications

No indication recorded.